本文已被：浏览 655次 下载 349次
投稿时间：2021-07-07 网络发布日期：2022-04-20
投稿时间：2021-07-07 网络发布日期：2022-04-20
中文摘要: 目的 分析上皮性卵巢癌（EOC）患者组蛋白甲基化转移酶3 SMYD3表达水平及其与化疗耐药、预后的关系。
方法 收集2015年11月至2017年11月经中国医科大学附属盛京医院确诊并进行手术的98份EOC组织标本与相应的98份癌旁组织标本（距肿瘤边缘4 cm处）。采用免疫组织化学染色法检测SMYD3表达水平，采用Spearman等级相关分析SMYD3与化疗耐药的相关性，Cox回归分析探讨EOC患者预后的影响因素。
结果 EOC组织中SMYD3高表达率明显高于癌旁组织（68.37% vs 28.57%，P＜0.01）；SMYD3高表达与FIGO分期、分化程度、淋巴结转移、铂反应有关（P＜0.05）；SMYD3表达高低与化疗耐药呈正相关（r=0.662，P＜0.01）。随访时间3～36个月，中位生存期26个月，其中SMYD3高表达、低表达者中位生存期分别为20、34个月，两者比较差异有统计学意义（P＜0.01）。单因素分析示，FIGOⅢ+Ⅳ期、肿瘤低分化、淋巴结转移、 SMYD3高表达、化疗耐药EOC患者的生存时间均显著缩短（P＜0.05,P＜0.01）；多因素Cox回归分析示，肿瘤低分化、淋巴结转移、FIGO Ⅲ+Ⅳ期、SMYD3高表达、化疗耐药均是影响EOC预后的独立危险因素（P＜0.05）。
结论 SMYD3表达在EOC组织中明显高于癌旁组织，且SMYD3表达与化疗耐药呈正相关，高表达患者更容易出现复发，预后较差，SMYD3有望作为EOC诊治的生物标志物。
中文关键词: 上皮性卵巢癌 SET及MYND结构域包含蛋白3 组蛋白甲基化转移酶3 化疗耐药 预后
Abstract:Objective To investigate the expression of histone methyltransferase 3 SMYD3 in patients with epithelial ovarian cancer（EOC） and its correlation with chemoresistance and prognosis.
Methods From November 2015 to November 2017, 98 EOC tissue samples and 98 corresponding adjacent tissue samples （4 cm away from the edge of the tumor）diagnosed and operated in Shengjing Hospital of China Medical University were collected. Immunohistochemical staining was used to detect the expression level of SMYD3. Spearman rank correlation was used to analyze the correlation between SMYD3 and chemoresistance, and Cox regression analysis was used to explore the prognostic factors of patients with EOC.
Results The high expression rate of SMYD3 in EOC tissues was significantly higher than that in paracancerous tissues （68.37% vs 28.57%, P＜0.01）. The high expression of SMYD3 was related to the FIGO stage, degree of differentiation, lymph node metastasis, and platinum response of EOC（P＜0.05）. The expression of SMYD3 was positively correlated with chemoresistance （r=0.662, P＜0.01）. The follow-up time was 3 to 36 months, and the median survival time was 26 months. There was a statistical difference in the median survival time between high expression and low expression of SMYD3 （20 month vs 34 month, P＜0.01）. Univariate analysis showed that the survival time of EOC patients with FIGO stage Ⅲ+Ⅳ, poorly differentiated tumor, lymph node metastasis, high SMYD3 expression, and chemoresistance were significantly shortened （P＜0.05,P＜0.01）. Multivariate Cox regression analysis showed that poor tumor differentiation, lymph node metastasis, FIGO Ⅲ+Ⅳ stage, high expression of SMYD3, and chemoresistance were all independent risk factors affecting the prognosis of EOC（P＜0.05）.
Conclusion SMYD3 expression is significantly higher in EOC tissue than that in paracancerous tissues, and SMYD3 expression is positively correlated with chemoresistance. Patients with high expression of SMYD3 are more likely to relapse and have a poor prognosis. SMYD3 is expected to be used as a biomarker for the diagnosis and treatment of EOC.
keywords: Epithelial ovarian cancer SET and MYND domain containing 3 Histone methyltransferase 3 Chemoresistance Prognosis
文章编号： 中图分类号：R737.31 文献标志码：A
基金项目:辽宁省教育厅科学研究经费项目（ZF2019021）
附件
| Author Name | Affiliation |
| ZHANG Tao, CHANG Ying, ZHU Jun-nan, JIN Ming-xian, YU Xi | Department of Gynecology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110000, China |
引用文本：
张涛，常颖，朱俊南，金明仙，于溪.上皮性卵巢癌患者SMYD3蛋白表达与化疗耐药、预后的相关性分析[J].中国临床研究,2022,35(4):483-486.
张涛，常颖，朱俊南，金明仙，于溪.上皮性卵巢癌患者SMYD3蛋白表达与化疗耐药、预后的相关性分析[J].中国临床研究,2022,35(4):483-486.